* ACTG A5163: Bone loss is a problem associated with HIV infection and possibly HIV treatment. This study will look at the effectiveness of alendronate (brand name: Fosamax) plus calcium and vitamin D for treating bone loss in people with HIV. To participate in this study, you must have a viral load less than 1000, a T cell count greater than 100, and be on HIV medications for at least 12 weeks with good virus control. Also, you should not plan on changing your diet or exercise habits for the 48 weeks of the study.
* ACTG 5093: Depo-medroxyprogesterone or DMPA (brand name: Depo-Provera) is a hormone treatment for women that helps regulate the menstrual cycle and is sometimes used for birth control, among other purposes. This study will look for possible drug interactions with HIV drugs. To participate in this 12-week study, females with HIV must have a viral load less than 10,000 and T cells greater than 200. Also, you cannot have taken DMPA within 180 days before the study, and you cannot have been through menopause. DMPA, but not HIV medications, will be provided for this study.
* ACTG A5127: This study will look at the treatment of hepatitis B in HIV+ patients for whom Epivir will not work because of hepatitis B drug resistance. Participants will be given adefovir (brand name: Hepsera) or Viread to treat the hepatitis B. You must be co-infected with HIV and hepatitis B, with an HIV viral load less than 10,000 and a hepatitis B viral load more than 1 million. You cannot have hepatitis C or hepatitis D. You should be taking HIV therapy with good virus control; you should not be taking Ziagen (which is also in Trizivir).
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Clinical Trial Information|
|Publication:||HIV Treatment: ALERTS!|
|Date:||Oct 1, 2003|
|Previous Article:||Baylor College of Medicine.|
|Next Article:||Montrose Clinic.|